At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 98 enrolled
Drug / intervention
18F-Fluorocholine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
18F-Fluorocholine for the Detection of Parathyroid Adenomas
In Brief
A Phase 3 clinical trial evaluating 18F-Fluorocholine and Positron Emission Tomography (PET) for Hyperparathyroidism, Primary. Completed, enrolled 98 participants across 1 site.
Detailed Summary
The investigators are studying the ability of F18 labeled fluorocholine PET to localize parathyroid adenomas in patients with hyperparathyroidism prior to surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperparathyroidism, Primary
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartSep 2016
First PostedDec 2018
Primary CompletionMay 2021
TodayJul 2026
First PostedDec 4, 2018
Enrollment StartSep 21, 2016
Primary CompletionMay 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 7.6 years ago
Interventions
18F-Fluorocholinedrug
Given intravenously
Positron Emission Tomography (PET)procedure
Imaging technique that uses radioactive agents known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities